Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17NO5 |
Molecular Weight | 339.342 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=NOC(CC(O)=O)=C2C3=CC=C(OC)C=C3
InChI
InChIKey=DJEIHHYCDCTAAH-UHFFFAOYSA-N
InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/16473424Curator's Comment: description was created based on several sources, including
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16473424
Curator's Comment: description was created based on several sources, including
Mofezolac is an NSAID ) (non-steroidal anti-inflammatory drug), which acts via the cyclooxygenase enzyme, preferentially to COX-1. It also has potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. It was introduced for the treatment of postoperative and posttraumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. It marketed only in Japan by Yoshitomi Pharmaceutical Ltd. Japan, was approved in July 1994.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9777656 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Disopain Approved Useused to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction. Launch Date1994 |
|||
Primary | Disopain Approved Useused to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction. Launch Date1994 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. | 2002 Sep |
|
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. | 2003 Oct |
|
Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. | 2006 Apr |
|
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. | 2006 Oct |
|
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. | 2008 Mar 18 |
|
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. | 2009 |
|
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. | 2010 Jun 15 |
Patents
Sample Use Guides
General dosage regimen (for adults): Take 1 tablet (75mg of the active ingredient) at a time three times a day after meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19198759
Mofezolac affected neither the number of TRAP-positive multinucleated cells nor the extent of lacunar resorption pits.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11469
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
C054999
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
100000080373
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
1829
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
MOFEZOLAC
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
C66176
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
RVJ0BV3H3Y
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
DTXSID1046716
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
SUB09035MIG
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
78967-07-4
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
6701
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL259972
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | |||
|
m7588
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
4237
Created by
admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY